REGENXBIO (RGNX) Stock Price, News & Analysis

Company Overview

REGENXBIO Inc. is a clinical-stage biotechnology company focused on the development of gene therapies for patients with serious diseases. The company’s proprietary NAV® (Natural AAV Vector) platform utilizes a collection of adeno-associated viral (AAV) vectors designed to efficiently deliver therapeutic genes to target cells. By harnessing naturally occurring AAVs and employing advanced molecular engineering, REGENXBIO aims to maximize the precision, durability and safety of gene-based treatments across a range of conditions.

The company’s pipeline spans both rare genetic disorders and more prevalent diseases of significant unmet need. Key programs include RGX-314, an investigational therapy for wet age-related macular degeneration; RGX-111 and RGX-121 for mucopolysaccharidosis types I and II respectively; and RGX-501 for the treatment of sickle cell disease. Each program leverages tissue-specific promoters and targeted AAV serotypes to optimize gene expression in the eye, central nervous system or liver, depending on the therapeutic indication.

With its headquarters in Rockville, Maryland, REGENXBIO operates in the United States and collaborates with global partners to advance its product candidates through clinical development and regulatory pathways. The company has established manufacturing capabilities in Maryland and Maryland-based facilities to support Good Manufacturing Practice (GMP) production, while partnering with third-party contract development and manufacturing organizations to scale toward commercial supply. Strategic alliances with industry leaders have furthered development efforts and expanded the company’s access to key expertise and resources.

Founded in 2012 by gene therapy innovators including founders Kenneth A. Simon and Richard Fisher, REGENXBIO has grown under the leadership of President and Chief Executive Officer Kenneth A. Mills. The executive team features seasoned professionals in biopharmaceutical development, regulatory affairs and manufacturing. Through continued investment in its NAV platform and disciplined clinical execution, REGENXBIO is positioned to advance transformative gene therapies that target the root causes of disease.

Key Stats

• Today's Range: $8.39 to $8.78
• 50-Day Range: $7.13 to $10.40
• 52-Week Range: $5.04 to $15.36
• Volume: 679,975 shs
• Average Volume: 929,241 shs
• Market Capitalization: $422.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.63
• Consensus Rating: Moderate Buy

REGENXBIO Stock Analysis - MarketRank™

REGENXBIO scored higher than 89% of companies evaluated by MarketBeat, and ranked 103rd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

REGENXBIO has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for REGENXBIO are expected to grow in the coming year, from ($4.84) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of REGENXBIO is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of REGENXBIO is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

REGENXBIO has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.60% of the float of REGENXBIO has been sold short.

Short Interest Ratio / Days to Cover

REGENXBIO has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in REGENXBIO has recently decreased by 8.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

REGENXBIO does not currently pay a dividend.

Dividend Growth

REGENXBIO does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.82

Percentage of Shares Shorted

12.60% of the float of REGENXBIO has been sold short.

Short Interest Ratio / Days to Cover

REGENXBIO has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in REGENXBIO has recently decreased by 8.47%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.75

News Sentiment

REGENXBIO has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for REGENXBIO this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for RGNX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $162,962.00 in company stock.

Percentage Held by Insiders

12.79% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RGNX Stock Analysis - Frequently Asked Questions

How have RGNX shares performed this year?

REGENXBIO's stock was trading at $7.73 at the start of the year. Since then, RGNX stock has increased by 9.1% and is now trading at $8.43.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its earnings results on Monday, May, 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by $0.29. The biotechnology company had revenue of $89.01 million for the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative trailing twelve-month return on equity of 53.29% and a negative net margin of 100.62%.
Read the conference call transcript.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that REGENXBIO investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RGNX
• CIK: 1590877
• Web: www.regenxbio.com
• Phone: (240) 552-8181
• Fax: N/A
• Employees: 370
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.63
• High Stock Price Target: $52.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +270.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$227.10 million
• Net Margins: -100.62%
• Pretax Margin: -100.62%
• Return on Equity: -53.29%
• Return on Assets: -30.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $83.33 million
• Price / Sales: 5.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.24 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 50,160,000
• Free Float: 43,745,000
• Market Cap: $427.91 million
• Optionable: Optionable
• Beta: 1.06